SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease
Background Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studie...
Saved in:
| Published in | Molecular neurodegeneration Vol. 16; no. 1; pp. 46 - 18 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
02.07.2021
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1750-1326 1750-1326 |
| DOI | 10.1186/s13024-021-00468-x |
Cover
| Abstract | Background
Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance.
Methods
We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons.
Results
Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130.
Conclusions
Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. |
|---|---|
| AbstractList | Human tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance.BACKGROUNDHuman tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance.We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons.METHODSWe used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons.Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130.RESULTSOur study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130.Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon.CONCLUSIONSOur findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. Background Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance. Methods We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons. Results Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130. Conclusions Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. Background Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance. Methods We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons. Results Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130. Conclusions Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. Background Human tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance. Methods We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons. Results Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130. Conclusions Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. Keywords: Lysine methylation , Protein methyl transferase , Nuclear tau , Posttranslational modification Abstract Background Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance. Methods We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons. Results Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130. Conclusions Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. Human tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance. We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons. Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130. Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. Human tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which parallel the formation of insoluble Tau aggregates, neuronal dysfunction and degeneration. While PTMs on aggregated Tau have been studied in detail, much less is known about the modification patterns of soluble Tau. Furthermore, PTMs other than phosphorylation have only come into focus recently and are still understudied. Soluble Tau species are likely responsible for the spreading of pathology during disease progression and are currently being investigated as targets for immunotherapies. A better understanding of their biochemical properties is thus of high importance. We used a mass spectrometry approach to characterize Tau PTMs on a detergent-soluble fraction of human AD and control brain tissue, which led to the discovery of novel lysine methylation events. We developed specific antibodies against Tau methylated at these sites and biochemically characterized methylated Tau species in extracts from human brain, the rTg4510 mouse model and in hiPSC-derived neurons. Our study demonstrates that methylated Tau levels increase with Tau pathology stage in human AD samples as well as in a mouse model of Tauopathy. Methylated Tau is enriched in soluble brain extracts and is not associated with hyperphosphorylated, high molecular weight Tau species. We also show that in hiPSC-derived neurons and mouse brain, methylated Tau preferentially localizes to the cell soma and nuclear fractions and is absent from neurites. Knock down and inhibitor studies supported by proteomics data led to the identification of SETD7 as a novel lysine methyltransferase for Tau. SETD7 specifically methylates Tau at K132, an event that facilitates subsequent methylation at K130. Our findings indicate that methylated Tau has a specific somatic and nuclear localization, suggesting that the methylation of soluble Tau species may provide a signal for their translocation to different subcellular compartments. Since the mislocalization and depletion of Tau from axons is associated with tauopathies, our findings may shed light onto this disease-associated phenomenon. |
| ArticleNumber | 46 |
| Audience | Academic |
| Author | Jin, Liang Hu, Chenqi Ehrnhoefer, Dagmar E. Prat Oriol, Nuria Neu, Marie Haberkant, Per Gomez Ramos, Borja Tian, Yu Schwärzler, Vera Ried, Janina S. Ercan-Herbst, Ebru Schöndorf, David C. Wang, Xue Bichmann, Maria Schlüter, Annabelle Gasparini, Laura |
| Author_xml | – sequence: 1 givenname: Maria surname: Bichmann fullname: Bichmann, Maria organization: BioMed X Institute – sequence: 2 givenname: Nuria surname: Prat Oriol fullname: Prat Oriol, Nuria organization: BioMed X Institute, Present address: Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology – sequence: 3 givenname: Ebru surname: Ercan-Herbst fullname: Ercan-Herbst, Ebru organization: BioMed X Institute – sequence: 4 givenname: David C. surname: Schöndorf fullname: Schöndorf, David C. organization: BioMed X Institute, AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery – sequence: 5 givenname: Borja surname: Gomez Ramos fullname: Gomez Ramos, Borja organization: BioMed X Institute, Present address: Life Sciences Research Unit, University of Luxembourg, Luxembourg Centre for Systems Biomedicine, University of Luxembourg – sequence: 6 givenname: Vera surname: Schwärzler fullname: Schwärzler, Vera organization: BioMed X Institute – sequence: 7 givenname: Marie surname: Neu fullname: Neu, Marie organization: AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery – sequence: 8 givenname: Annabelle surname: Schlüter fullname: Schlüter, Annabelle organization: AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery – sequence: 9 givenname: Xue surname: Wang fullname: Wang, Xue organization: AbbVie Bioresearch Center (ABC) – sequence: 10 givenname: Liang surname: Jin fullname: Jin, Liang organization: AbbVie Bioresearch Center (ABC) – sequence: 11 givenname: Chenqi surname: Hu fullname: Hu, Chenqi organization: AbbVie Bioresearch Center (ABC) – sequence: 12 givenname: Yu surname: Tian fullname: Tian, Yu organization: AbbVie Bioresearch Center (ABC) – sequence: 13 givenname: Janina S. surname: Ried fullname: Ried, Janina S. organization: AbbVie Deutschland GmbH & Co. KG, Genomics Research Center – sequence: 14 givenname: Per surname: Haberkant fullname: Haberkant, Per organization: European Molecular Biology Laboratory (EMBL) – sequence: 15 givenname: Laura surname: Gasparini fullname: Gasparini, Laura organization: AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery – sequence: 16 givenname: Dagmar E. orcidid: 0000-0003-3411-5415 surname: Ehrnhoefer fullname: Ehrnhoefer, Dagmar E. email: dagmar.ehrnhoefer@abbvie.com organization: BioMed X Institute, AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34215303$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhS1URNuBF2CBIrFhk-K_JM4GaVQKVKqEBMPacpLrGY8Su9hJ1bLiNXg9noTbmVJmKlR5keT6O8e-N-eYHPjggZCXjJ4wpsq3iQnKZU45yymVpcqvn5AjVhU0Z4KXBzvvh-Q4pTVCFaXFM3IoJGeFoOKIfPl6tnhf5QN0zozQZUPwYYBxddOb0QWfuZSBj65d4R5-ptBPTQ_ZwkyZ89m8_7ECN0D8_fNXyjqXwCR4Tp5a0yd4cfeckW8fzhann_KLzx_PT-cXeVvSasx5AV1VdI2ShW3KurZUmdYYMLySyqiaYYVKWzHVStEZq6qiMZQx2ZSNEdyKGTnf-nbBrPVldIOJNzoYpzeFEJfaxNG1Pei6axpVlVIaW0lWQ403sB3jogGwzcbr3dbrcmpwFi34MZp-z3R_x7uVXoYrrXgh8S-gwZs7gxi-T5BGPbjUQt8bD2FKGjElaS1kiejrB-g6TNHjqJAqBK_LUuxQS4MNOG8Dntvemup5WXHBRI1rRk7-Q-HqYHAtxsU6rO8JXu02et_h30QgwLdAG0NKEew9wqi-jZ3exk5j7PQmdvoaReqBqHXjJkB4Hdc_LhVbacJz_BLiv2k8ovoDMFfsFA |
| CitedBy_id | crossref_primary_10_1186_s13062_024_00484_z crossref_primary_10_3390_cells13080719 crossref_primary_10_1007_s12031_022_02002_0 crossref_primary_10_1002_ibra_12176 crossref_primary_10_3390_ijms24098286 crossref_primary_10_1016_j_joto_2024_07_008 crossref_primary_10_1093_procel_pwae026 crossref_primary_10_3390_biom14070862 crossref_primary_10_1080_21655979_2022_2045830 crossref_primary_10_4103_NRR_NRR_D_23_01742 crossref_primary_10_3389_fimmu_2024_1384516 crossref_primary_10_1002_mco2_674 crossref_primary_10_2174_0115672050301407240408033046 |
| Cites_doi | 10.1084/jem.20160833 10.1016/j.celrep.2020.107908 10.3233/JAD-170959 10.1042/BJ20140372 10.1016/j.stemcr.2017.08.019 10.1038/ncomms1255 10.1038/nprot.2015.101 10.1021/acs.analchem.5b04509 10.3233/JAD-190604 10.1523/JNEUROSCI.3279-05.2005 10.1186/s40478-019-0831-2 10.1111/febs.14056 10.1038/nn.3639 10.1016/j.molcel.2008.03.022 10.1038/sdata.2018.185 10.1074/jbc.M703269200 10.1038/nn.4067 10.1038/s41392-018-0017-6 10.1186/s40478-017-0489-6 10.1016/j.chembiol.2010.11.014 10.1186/s13024-016-0109-0 10.1111/febs.14587 10.1186/s40478-020-01117-y 10.1016/j.molcel.2019.08.026 10.1038/s41591-020-0938-9 10.1038/sdata.2016.89 10.1093/bioinformatics/bts635 10.1038/nature03117 10.1038/s41582-020-0333-7 10.1016/j.nbd.2019.104518 10.1016/j.cell.2020.10.029 10.1016/j.scr.2018.11.012 10.1126/science.1113694 10.1016/j.neuron.2018.06.003 10.1186/gb-2014-15-2-r29 10.1038/ncomms9490 10.1002/msb.134974 10.1073/pnas.1407358111 10.1186/s40478-018-0565-6 10.1016/j.bbadis.2004.06.020 10.1016/j.cell.2020.01.027 10.1093/nar/gky1106 10.3389/fncel.2018.00202 10.1038/nrn.2015.1 10.1038/srep00700 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13024-021-00468-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Database Suite (ProQuest) ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1750-1326 |
| EndPage | 18 |
| ExternalDocumentID | oai_doaj_org_article_9dbb87644af7419e9607fd123beefb2f PMC8254302 A672313939 34215303 10_1186_s13024_021_00468_x |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Massachusetts Netherlands |
| GeographicLocations_xml | – name: Massachusetts – name: Netherlands |
| GrantInformation_xml | – fundername: AbbVie grantid: n.a. funderid: http://dx.doi.org/10.13039/100006483 – fundername: NINDS NIH HHS grantid: U24 NS072026 – fundername: NIA NIH HHS grantid: U01 AG006786 – fundername: NIA NIH HHS grantid: P50 AG025711 – fundername: NINDS NIH HHS grantid: R01 NS080820 – fundername: NIA NIH HHS grantid: P50 AG016574 – fundername: NIA NIH HHS grantid: R01 AG032990 – fundername: NIA NIH HHS grantid: U01 AG046139 – fundername: NIA NIH HHS grantid: R01 AG018023 – fundername: NIA NIH HHS grantid: P01 AG003949 – fundername: NIA NIH HHS grantid: P30 AG019610 – fundername: ; grantid: n.a. |
| GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR IPY ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-25ed75db845fb699f08acaaea2748a8919f004f718c43daf875ba0114b6ba32f3 |
| IEDL.DBID | M48 |
| ISSN | 1750-1326 |
| IngestDate | Wed Aug 27 00:53:49 EDT 2025 Thu Aug 21 14:18:24 EDT 2025 Sun Aug 24 04:13:18 EDT 2025 Fri Jul 25 06:36:18 EDT 2025 Tue Jun 17 21:36:22 EDT 2025 Tue Jun 10 20:38:01 EDT 2025 Mon Jul 21 06:04:37 EDT 2025 Thu Apr 24 23:07:20 EDT 2025 Tue Jul 01 01:59:05 EDT 2025 Sat Sep 06 07:29:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Posttranslational modification Nuclear tau Lysine methylation Protein methyl transferase |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-25ed75db845fb699f08acaaea2748a8919f004f718c43daf875ba0114b6ba32f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-3411-5415 |
| OpenAccessLink | https://www.proquest.com/docview/2553296636?pq-origsite=%requestingapplication% |
| PMID | 34215303 |
| PQID | 2553296636 |
| PQPubID | 55149 |
| PageCount | 18 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9dbb87644af7419e9607fd123beefb2f pubmedcentral_primary_oai_pubmedcentral_nih_gov_8254302 proquest_miscellaneous_2548409346 proquest_journals_2553296636 gale_infotracmisc_A672313939 gale_infotracacademiconefile_A672313939 pubmed_primary_34215303 crossref_primary_10_1186_s13024_021_00468_x crossref_citationtrail_10_1186_s13024_021_00468_x springer_journals_10_1186_s13024_021_00468_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-02 |
| PublicationDateYYYYMMDD | 2021-07-02 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Molecular neurodegeneration |
| PublicationTitleAbbrev | Mol Neurodegeneration |
| PublicationTitleAlternate | Mol Neurodegener |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | CJ Huseby (468_CR36) 2019; 71 K Santacruz (468_CR21) 2005; 309 A Behrendt (468_CR20) 2019; 130 T Arakhamia (468_CR9) 2020; 180 A Dobin (468_CR33) 2013; 29 K Subramanian (468_CR48) 2008; 30 N Sergeant (468_CR6) 2005; 1739 Z Wu (468_CR50) 2017; 284 M Morris (468_CR25) 2015; 18 E Barini (468_CR18) 2020 YW Wan (468_CR32) 2020; 32 I Sotiropoulos (468_CR5) 2017; 5 M Wang (468_CR31) 2018; 5 A Ittner (468_CR1) 2018; 99 S Chuikov (468_CR47) 2004; 432 B Frost (468_CR3) 2014; 17 TJ Cohen (468_CR45) 2011; 2 H Franken (468_CR24) 2015; 10 468_CR27 W Mair (468_CR14) 2016; 88 JP Quinn (468_CR11) 2018; 63 H Wesseling (468_CR10) 2020; 183 EM Rowe (468_CR41) 1707; 2019 S Lanouette (468_CR40) 2014; 10 RC Team (468_CR35) 2021 ML Choi (468_CR15) 2018; 285 D Barsyte-Lovejoy (468_CR29) 2014; 111 S Dujardin (468_CR17) 2020; 26 DC Schondorf (468_CR51) 2018; 34 S Takeda (468_CR19) 2015; 6 JZ Wang (468_CR44) 2013; 33 Y Wang (468_CR8) 2016; 17 K Schlegel (468_CR23) 2019; 7 A Dhayalan (468_CR42) 2011; 18 IAA Batista (468_CR49) 2018; 3 PD Sohn (468_CR2) 2016; 11 E Ercan-Herbst (468_CR7) 2019; 7 ML Ritter (468_CR46) 2018; 12 C Wang (468_CR28) 2017; 9 DP Hanger (468_CR13) 2007; 282 JL Guo (468_CR22) 2016; 213 M Ramsden (468_CR37) 2005; 25 N Bengoa-Vergniory (468_CR39) 2021; 9 MB Maina (468_CR4) 2018; 6 Y Perez-Riverol (468_CR26) 2019; 47 CW Law (468_CR34) 2014; 15 KE Funk (468_CR12) 2014; 462 CA Lasagna-Reeves (468_CR16) 2012; 2 C Peng (468_CR43) 2020; 16 EM Cornett (468_CR38) 2019; 75 M Allen (468_CR30) 2016; 3 |
| References_xml | – volume: 2019 start-page: 164 year: 1707 ident: 468_CR41 publication-title: Brain Res – volume: 213 start-page: 2635 issue: 12 year: 2016 ident: 468_CR22 publication-title: J Exp Med doi: 10.1084/jem.20160833 – volume: 32 start-page: 107908 issue: 2 year: 2020 ident: 468_CR32 publication-title: Cell Rep doi: 10.1016/j.celrep.2020.107908 – volume: 7 start-page: 192 issue: 1 year: 2019 ident: 468_CR7 publication-title: A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain: Acta Neuropath Commun. – volume: 63 start-page: 13 issue: 1 year: 2018 ident: 468_CR11 publication-title: J Alzheimers Dis doi: 10.3233/JAD-170959 – volume: 462 start-page: 77 issue: 1 year: 2014 ident: 468_CR12 publication-title: Biochem J doi: 10.1042/BJ20140372 – volume: 9 start-page: 1221 issue: 4 year: 2017 ident: 468_CR28 publication-title: Stem Cell Rep doi: 10.1016/j.stemcr.2017.08.019 – volume: 2 start-page: 252 year: 2011 ident: 468_CR45 publication-title: Nat Commun doi: 10.1038/ncomms1255 – volume: 10 start-page: 1567 issue: 10 year: 2015 ident: 468_CR24 publication-title: Nat Protoc doi: 10.1038/nprot.2015.101 – volume: 88 start-page: 3704 issue: 7 year: 2016 ident: 468_CR14 publication-title: Anal Chem doi: 10.1021/acs.analchem.5b04509 – volume: 71 start-page: 979 year: 2019 ident: 468_CR36 publication-title: J Alzheimers Dis doi: 10.3233/JAD-190604 – volume: 25 start-page: 10637 issue: 46 year: 2005 ident: 468_CR37 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3279-05.2005 – volume: 7 start-page: 177 issue: 1 year: 2019 ident: 468_CR23 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-019-0831-2 – volume: 284 start-page: 2732 issue: 17 year: 2017 ident: 468_CR50 publication-title: FEBS J doi: 10.1111/febs.14056 – volume: 17 start-page: 357 issue: 3 year: 2014 ident: 468_CR3 publication-title: Nat Neurosci doi: 10.1038/nn.3639 – volume: 30 start-page: 336 issue: 3 year: 2008 ident: 468_CR48 publication-title: Mol Cell doi: 10.1016/j.molcel.2008.03.022 – volume: 5 start-page: 180185 year: 2018 ident: 468_CR31 publication-title: Sci Data doi: 10.1038/sdata.2018.185 – volume: 282 start-page: 23645 issue: 32 year: 2007 ident: 468_CR13 publication-title: J Biol Chem doi: 10.1074/jbc.M703269200 – ident: 468_CR27 – volume: 18 start-page: 1183 issue: 8 year: 2015 ident: 468_CR25 publication-title: Nat Neurosci doi: 10.1038/nn.4067 – volume: 3 start-page: 19 year: 2018 ident: 468_CR49 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-018-0017-6 – volume: 5 start-page: 91 issue: 1 year: 2017 ident: 468_CR5 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-017-0489-6 – volume: 18 start-page: 111 issue: 1 year: 2011 ident: 468_CR42 publication-title: Chem Biol doi: 10.1016/j.chembiol.2010.11.014 – volume: 11 start-page: 47 issue: 1 year: 2016 ident: 468_CR2 publication-title: Mol Neurodegener doi: 10.1186/s13024-016-0109-0 – volume: 285 start-page: 3631 issue: 19 year: 2018 ident: 468_CR15 publication-title: FEBS J doi: 10.1111/febs.14587 – volume: 9 start-page: 18 issue: 1 year: 2021 ident: 468_CR39 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-020-01117-y – volume: 75 start-page: 1092 issue: 6 year: 2019 ident: 468_CR38 publication-title: Mol Cell doi: 10.1016/j.molcel.2019.08.026 – volume: 26 start-page: 1256 year: 2020 ident: 468_CR17 publication-title: Nat Med doi: 10.1038/s41591-020-0938-9 – volume: 3 start-page: 160089 year: 2016 ident: 468_CR30 publication-title: Sci Data. doi: 10.1038/sdata.2016.89 – volume: 29 start-page: 15 issue: 1 year: 2013 ident: 468_CR33 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts635 – volume: 432 start-page: 353 issue: 7015 year: 2004 ident: 468_CR47 publication-title: Nature doi: 10.1038/nature03117 – volume: 16 start-page: 199 issue: 4 year: 2020 ident: 468_CR43 publication-title: Nat Rev Neurol doi: 10.1038/s41582-020-0333-7 – volume: 130 start-page: 104518 year: 2019 ident: 468_CR20 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2019.104518 – volume-title: Tau in the brain interstitial fluid is fragmented and seeding-competent year: 2020 ident: 468_CR18 – volume: 183 start-page: 1699 year: 2020 ident: 468_CR10 publication-title: Cell doi: 10.1016/j.cell.2020.10.029 – volume: 33 start-page: S123 issue: Suppl 1 year: 2013 ident: 468_CR44 publication-title: J Alzheimers Dis – volume: 34 start-page: 101351 year: 2018 ident: 468_CR51 publication-title: Stem Cell Res doi: 10.1016/j.scr.2018.11.012 – volume: 309 start-page: 476 issue: 5733 year: 2005 ident: 468_CR21 publication-title: Science doi: 10.1126/science.1113694 – volume: 99 start-page: 13 issue: 1 year: 2018 ident: 468_CR1 publication-title: Neuron doi: 10.1016/j.neuron.2018.06.003 – volume: 15 start-page: R29 issue: 2 year: 2014 ident: 468_CR34 publication-title: Genome Biol doi: 10.1186/gb-2014-15-2-r29 – volume: 6 start-page: 8490 year: 2015 ident: 468_CR19 publication-title: Nat Commun doi: 10.1038/ncomms9490 – volume-title: R: A language and environment for statistical computing year: 2021 ident: 468_CR35 – volume: 10 start-page: 724 year: 2014 ident: 468_CR40 publication-title: Mol Syst Biol doi: 10.1002/msb.134974 – volume: 111 start-page: 12853 issue: 35 year: 2014 ident: 468_CR29 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1407358111 – volume: 6 start-page: 70 issue: 1 year: 2018 ident: 468_CR4 publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-018-0565-6 – volume: 1739 start-page: 179 issue: 2–3 year: 2005 ident: 468_CR6 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbadis.2004.06.020 – volume: 180 start-page: 633 issue: 4 year: 2020 ident: 468_CR9 publication-title: Cell doi: 10.1016/j.cell.2020.01.027 – volume: 47 start-page: D442 issue: D1 year: 2019 ident: 468_CR26 publication-title: Nucleic Acids Res doi: 10.1093/nar/gky1106 – volume: 12 start-page: 202 year: 2018 ident: 468_CR46 publication-title: Front Cell Neurosci doi: 10.3389/fncel.2018.00202 – volume: 17 start-page: 5 issue: 1 year: 2016 ident: 468_CR8 publication-title: Nat Rev Neurosci doi: 10.1038/nrn.2015.1 – volume: 2 start-page: 700 year: 2012 ident: 468_CR16 publication-title: Sci Rep doi: 10.1038/srep00700 |
| SSID | ssj0047005 |
| Score | 2.3748882 |
| Snippet | Background
Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau,... Human tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau, which... Background Human tauopathies including Alzheimer's disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau,... Background Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern of Tau,... Abstract Background Human tauopathies including Alzheimer’s disease (AD) are characterized by alterations in the post-translational modification (PTM) pattern... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 46 |
| SubjectTerms | Advertising executives Alzheimer Disease - metabolism Alzheimer's disease Analysis Animal welfare Animals Antibodies Biomedical and Life Sciences Biomedicine Brain Brain research Dementia Detergents, Synthetic Development and progression Histone-Lysine N-Methyltransferase - metabolism Humans Immunization Immunotherapy Laboratory animals Localization Lysine Lysine - metabolism Lysine methylation Mass spectrometry Mass spectroscopy Medical research Medicine, Experimental Methylation Methyltransferase Mice Mice, Transgenic Molecular Medicine Molecular weight Neurodegeneration Neurodegenerative diseases Neurology Neurons Neurosciences Nuclear tau Pathology Peptides Phosphatase Phosphorylation Post-translation Post-translational modification Posttranslational modification Protein methyl transferase Protein Processing, Post-Translational - physiology Proteins Proteomics Research Article Scientific imaging Species Tau protein tau Proteins - metabolism Transferases |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQUH4CBRkJwQGibmzHP8cFWlVIcICt1JtlO7a60m5adXelwonX4PV4EmacZGmKgAvHjZ2VPfONZ754PCbkOfe6FoFVJVN1KIUHguIq7kqpQ0oOHBTLZRc_fJRHx-L9SX1y5aovzAnrygN3gts3jfdgsUK4BM7PRIi4VWrgL3yMybOEq-_ETAYy1a3BQgG4hiMyWu6vcHtOlJiOgIRQl5cjN5Sr9f--Jl9xStcTJq_tmmZndHib3OqjSDrtRn-H3IjtXbI7bYFBL7_QFzTndeYP5rvk0-eD2TtV5iMiEF7SJR5jiKCfLguOzlcUMIQZoQ2Fn4hFv4h05jZ03tLp4utpnC_jxY9v31e03865R44PD2Zvj8r-JoUygLjWJatjo-rGa1EnL41JE-2Cc9EBJ9VOmwqeTEQCPxUEb1wCEuMdUiUvveMs8ftkpz1r40NCuWoMczEkbxoB4aZxUjlduWhqD84wFqQaBGtDX2Ycb7tY2Ew3tLSdMiwow2Zl2MuCvNq-c94V2fhr7zeor21PLJCdHwBsbA8b-y_YFOQlatuiGcPwgutPI8AksSCWnUoFkS833BRkb9QTzC-Mmwe82N78VxZ4GmdAJLksyLNtM76JKW1tPNtgH4Hkmgvo86CD13ZKXEAkBsFFQdQIeKM5j1va-WkuDo6MHyRWkNcDRH8N688yffQ_ZPqY3GTZxBRY2h7ZWV9s4hMI2db-abbOn5rDPXY priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagXLggoPyEFmQkBAeIuokdOz6hBVpVSHCArbQ3y3ZsutJutmx2pZYTr8Hr8STMONmUFNFj4okUe2Y832ePx4S8YLYsuMuzNJeFS7kFgmIyZlJRuhAMBKg8ll389Fkcn_CP02LaLbg1XVrldk6ME3W1dLhGfgDQl-WAzZl4e_Y9xVujcHe1u0LjJrmVARLBqxvktCdcXIKJbQ_KlOKgwU06nmJSAtLCMj0fBKNYs__fmfmv0HQ1bfLK3mkMSUd3yZ0OS9Jxq_x75Iav75PdcQ08enFBX9KY3RmXzXfJl6-Hkw8yjQdFAGTSBR5m8KClNheOzhoKloR5oRWFR7RIO_d0YjZ0VtPx_Mepny386vfPXw3tNnUekJOjw8n747S7TyF1YiTXaV74ShaVLXkRrFAqjErjjPEGmGlpSpXBmxEPEK0cZ5UJQGWsQcJkhTUsD-wh2amXtX9MKJOVyo13waqKA-hURkhTZsarwkJI9AnJtgOrXVdsHO-8mOtIOkqhW2VoUIaOytDnCXndf3PWltq4Vvod6quXxDLZ8cVy9U13XqdVZS1M95ybAMhJeaBrMlRgf9b7YPOQkFeobY3ODL_nTHcmATqJZbH0WEjAv0wxlZD9gSQ4oRs2b-1Fd5NAoy9NNiHP-2b8EhPbar_coAxHis04yDxqzavvEuOAxwBiJEQODG_Q52FLPTuNJcKR98OIJeTN1kQvf-v_Y_rk-l7skdt5dB4JPrRPdtarjX8KkGxtn0W_-wPRfDQE priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQe-GCgPJIKchICA4QsYkdP47bpVWFBAfYSr1ZtmOrK-2mqLsr0Z76N_r3-CXMOMnSlIfEMfZYij3feOaLxxNCXjGnKu7LIi9l5XPugKDYgtlcKB-jBQdVprKLnz6Lo2P-8aQ66crk4F2Ym-f3hRLvl3iwxnNMJEAqp3KIF7craEQ0T8Sk33W5BDj1l2L-OG7geFJ9_t934Rtu6HaK5K1z0uR-Du-Te13cSMetoh-QO6F5SHbGDXDmxQV9TVMmZ_pEvkO-fD2YfpB5uhQCASVd4MWFABpp897obEkBNZgDWlN4RPS5eaBTu6azho7nl6dhtgjnP66ul7Q7wHlEjg8PppOjvPt3Qu7FSK7ysgq1rGqneBWd0DqOlPXWBgssVFmlC2gZ8QieyXNW2wi0xVkkR044y8rIHpOt5qwJTwllstalDT46XXMIMLUV0qrCBl05cH8hI0W_sMZ3hcXx_xZzkwiGEqZVhgFlmKQM8z0jbzdjvrVlNf4pvY_62khiSezUAEgxnYUZXTsHWzvnNkKUpANQMxlrwJoLIboyZuQNatug4cLredvdP4BJYgksMxYSYl2mmc7I3kASDM4Pu3u8mM7glwaYGSuBOjKRkZebbhyJSWxNOFujDEc6zTjIPGnhtZkS4xB7QTiRETkA3mDOw55mdprKgSPHhxXLyLseor9e6-9ruvt_4s_I3TIZkwSb2iNbq_N1eA7h2Mq9SHb4E9zGLUs priority: 102 providerName: Springer Nature |
| Title | SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease |
| URI | https://link.springer.com/article/10.1186/s13024-021-00468-x https://www.ncbi.nlm.nih.gov/pubmed/34215303 https://www.proquest.com/docview/2553296636 https://www.proquest.com/docview/2548409346 https://pubmed.ncbi.nlm.nih.gov/PMC8254302 https://doaj.org/article/9dbb87644af7419e9607fd123beefb2f |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-N7YUXBIyPwKiMhNgDBNrYseMHhLLSaarENLFW2ptlJzar1KbQD2njr-fsJoWMgXiKal8i23fXu5_vfAZ4RU2WsiLpxYlIi5gZBCi6R3XMs8I5jQYqCWUXP5_ykzEbXqQXO9Bcd1Qv4PJWaOfvkxovpu-uvl9_RIX_EBQ-4--XPvjGYp9s4OFeFqNPuRfiRT6Vj22jCkx0Q0ojWsxujCiMN4dobv1Gy1CFev5__mv_ZrZuplTeiKsGc3V8H-7VfibJN4LxAHZs9RD28wox9uyavCYh8zNsqe_D2flg9EnE4RAJOqBk5g86WOTgJk-OTJYEpcznjJYEf3ppNVNLRnpNJhXJpz8u7WRmF4dLUod7HsH4eDDqn8T1TQtxwbtiFSepLUVamoylznApXTfThdZWI2bNdCZ72NJlDu1YwWipHYIcoz2UMtxomjj6GHareWWfAqGilIm2hTOyZOiOSs2FznraytSgsbQR9JplVUVdhtzfhjFVAY5kXG1YoZAVKrBCXUXwZvvOt00Rjn9SH3lubSl9Ae3QMF98VbU-Klkag4aAMe3Qp5IWgZxwJUqmsdaZxEVw6HmtvODh8Apdn1bASfqCWSrnAj1jKqmM4KBFiepZtLsbaVGNdCvEcTRBoEl5BC-33f5Nn_JW2fna0zAPvilDmicb4dpOiTL01ND5iEC0xK4153ZPNbkMxcP9jgCuWARvGwH9Nay_r-mz_xjmc7ibBP0RqEYHsLtarO0L9NhWpgN3xIXowF6eD8-H-DwanJ59wdY-73fCLkgnKOpPd5A_TA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1JbxMxFH4q6QEuCCjLQAEjsRxg1GTs2Q4VSmmqlrYRKqnUm2vP2DRSMilZRMuJv8Gf4cfwS3jPmUmZInrrMWNPNPbbvme_BeAl10kosqDlB3GY-UKjg6JaXPlRklmr0EAFruzifjfaPhQfj8KjJfhV5cJQWGWlE52izkcZnZGvIfTlAWJzHr0__epT1yi6Xa1aaKiytUK-7kqMlYkdu-b8G7pwk_WdTaT3qyDY6vQ-bPtllwE_i5rx1A9Ck8dhrhMRWh2lqW0mKlPKKPTXEpWkLXzSFBZ1eCZ4riwCfK3IjdCRVjywHP_3BiwLOkBpwPJGp_vpoLIFIkYmr1J1kmhtQteEwqewCHJME_-sZg5d14B_bcNfxvFy4Oal21tnFLfuwO0SzbL2nP3uwpIp7sFKu0BPfnjOXjMXX-oO7lfg4HOntxn7LlUFYS4bUjqFQT6ZR-Ox_oQhL1Nkas7wJ8mEHhjWUzPWL1h78P3E9Idm_PvHzwkrr5Xuw-G17PUDaBSjwjwCxuM8DZTJrE5zgbA3VVGskpYyaajRKBsPWtXGyqwsd05dNwbSuT1JJOfEkEgM6Yghzzx4u3jndF7s48rZG0SvxUwq1O0ejMZfZCn3Ms21RoMjhLKI3VKDDmNsc5QAbYzVgfXgDVFbkjrBz8tUmRWBi6TCXLIdxYjAecpTD1ZrM1ENZPXhil9kqYYm8kJoPHixGKY3KbSuMKMZzRHk5HOBcx7O2WuxJC4QESLI8SCuMV5tzfWRon_iipTTyQPumAfvKha9-Kz_7-njq1fxHG5u9_b35N5Od_cJ3AqcIMUoT6vQmI5n5ikCxKl-Vkohg-PrFvw_5XV4Cg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQKyEuCCiPQAEjIThA1E3s-HEMtKuyQIXoVurNsh2brrSbrfYhASf-Bn-PX8LYSZamPCSOG4-l2PONZ771zAShp8SIgto8S3Ne2JQaICg6IzplwnqvwUHlse3i-yN2eEJHp8XphSr-mO3eXUk2NQ2hS1O92juvfGPigu0tw3UbTUN6QSB4IoUoclsUUgL92i7L0fGoO40pB5h1xTJ_nNlzSLFv_--n8wX3dDl18tL9aXRLwxvoehtP4rIBwE10xdW30E5ZA5eefcHPcMzwjH-d76CPxwfjfZ7GYhEINPEsFDQ40FSTD4cnSwxoCrmhFYafAZVm6vBYr_GkxuX065mbzNzix7fvS9xe7NxGJ8OD8evDtP2mQmrZgK_SvHAVLyojaOENk9IPhLZaOw3sVGghM3gyoB48lqWk0h7ojNGBNBlmNMk9uYO26nnt7iFMeCVz7aw3sqIQeErNuBaZdrIw4BZdgrJuY5VtG46H715MVSQegqlGGQqUoaIy1OcEvdjMOW_abfxT-lXQ10YytMqOD-aLT6q1PCUrY-DIp1R7iJ6kA8rGfQUYNM55k_sEPQ_aVsGg4fWsbusSYJGhNZYqGYcYmEgiE7TbkwRDtP3hDi-qPQiWChgbyYFSEpagJ5vhMDMkt9Vuvg4yNNBsQkHmbgOvzZIIhZgMwowE8R7wemvuj9STs9gmPHB_2LEEvewg-uu1_r6n9_9P_DG6-mF_qN69OXr7AF3Lo11xMK9dtLVarN1DiNhW5lFrlD8Br9c5-A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SETD7-mediated+monomethylation+is+enriched+on+soluble+Tau+in+Alzheimer%27s+disease&rft.jtitle=Molecular+neurodegeneration&rft.au=Bichmann%2C+Maria&rft.au=Prat+Oriol%2C+Nuria&rft.au=Ercan-Herbst%2C+Ebru&rft.au=Sch%C3%B6ndorf%2C+David+C&rft.date=2021-07-02&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=16&rft.issue=1&rft.spage=46&rft_id=info:doi/10.1186%2Fs13024-021-00468-x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon |